Clinical trials: Systemic Lupus
SLE (Systemic Lupus)
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity
- Trial name
- NCT06610409
- Testing
- blood sampling
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus
systemic lupus erythematosus (SLE) is the most common autoimmune disease in women of childbearing age. Promoting physical activity is a major national priority for the general population, including patients with chronic diseases.
- Trial name
- NCT05392790
- Testing
- Progressive resisted exercise training, Calcium and Vit D, Aerobic exercises
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Cairo University
Systemic Lupus Erythematosus
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.
- Trial name
- RECAST SLE OLE (NCT05430854)
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 7 more
- Volunteers
- 155 people
- Sponsor
- Amgen
Systemic Lupus Erthematosus
Bone Mineral Density in Patients With Childhood-onset Systemic Lupus Erythematous, in Relation to Disease Clinical Criteria
To determine the most common clinical characteristics in patients with childhood -onset systemic lupus erythematosus. To detect prevalence of low bone mineral density in patients with childhood -onset systemic lupus erythematosus.
- Trial name
- NCT06586359
- Volunteers
- 78 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus of Childhood
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE
Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage.
- Trial name
- NCT06586710
- Testing
- Assessment activation of interferon pathway
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Meyer Children's Hospital IRCCS
Systemic Lupus Erythematosus, Systemic Scleroderma Meeting
ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
Blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (SLE), but also from other immunomediated diseases (scleroderma, vasculitis, myositis…
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma Meeting, ANCA Vasculitis, Inflammatory Myositis
- Trial name
- PLAQUETTOLUP (NCT06593041)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
NAFLD - Nonalcoholic Fatty Liver Disease
Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients at Assiut University Hospital
Aim of the study :- 1. to estimate prevalence of non alcoholic fatty liver disease and liver fibrosis among Systemic lupus erythematosus patients 2.
- Trial name
- NAFLD and SLE (NCT06601361)
- Testing
- Fibroscan
- Volunteers
- 112 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
- Trial name
- NCT03845517
- Testing
- PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Lupus Erythematosus, Systemic
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage.
- Trial name
- DYSALARM-322 (NCT05193591)
- Testing
- Autoantibodies evaluation in lupus
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erythematosus
Exercise and Arterial Stiffness in Systemic Lupus Erythematosus
Patients with Systemic Lupus Erythematosus (SLE) have increased arterial stiffness, which leads to cardiovascular diseases (CVD) of arteriosclerotic origin, which are the main cause of mortality in these patients.
- Trial name
- EJERCITALES (NCT03107442)
- Testing
- Aerobic exercise
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
B-cell Tumors, Autoimmune Diseases
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases
- Conditions
- B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma
- Trial name
- NCT06567080
- Testing
- JWCAR201
- Where
- China
- Volunteers
- 15 people
- Sponsor
- RenJi Hospital
SLE (Systemic Lupus)
Effects of Nigella Sativa on T Cells and Cytokine Profile in Pediatric SLE Patients
The goal of this clinical trial is to learn if Nigella sativa oil works to improve SLEDAI Score in SLE pediatric student. It will also learn about the Treg, T helper cells, and cytokine of the patient.
- Trial name
- NCT06560775
- Testing
- Standard Treatment for SLE
- Where
- Indonesia
- Volunteers
- 32 people
- Sponsor
- University of Brawijaya
Systemic Lupus Erythematosus, SLE
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are receiving standard of care (SOC) therapy.
- Trial name
- NCT05688696
- Testing
- Orelabrutinib (Low Dose), Orelabrutinib (High Dose)
- Where
- 41 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects
This is a phase I, randomized, double-blind, placebo-controlled, dose-escalating clinical study aimed at evaluating the safety of TQB3702 tablets following single and multiple doses administered to healthy subjects
- Trial name
- NCT06448273
- Testing
- TQB3702 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis, Psoriatic Arthritis
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis
- Trial name
- TEMPLATE (NCT06544343)
- Testing
- Remote Monitoring, On site monitoring
- Where
- Italy
- Volunteers
- 190 people
- Sponsor
- University Of Perugia
Systemic Lupus Erythematous (SLE)
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
Background: The immune system is the body's defense against bacteria and other harmful invaders. In people with systemic lupus erythematosus (SLE), the immune system becomes overactive and attacks healthy cells by mistake.
- Trial name
- NCT04233164
- Testing
- Solu-Medrol 1mg/kg, Solu-Medrol 250 mg
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lupus Erythematosus, Systemic
Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)
The trial is designed to evaluate prevalence of fragility fracture, their impact on quality of life of SLE patients and disease or treatment variables such as steroids dosage or use of specific drugs like hydroxychloroquine…
- Trial name
- FRAIL (NCT05590390)
- Testing
- DXA, serum sample, PROs
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Lupus Erythematosus Disseminatus, Autoimmune Diseases
Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)
Systemic lupus erythematosus (SLE) is a severe autoimmune disease in which patients often develop numerous autoantibodies (Abs).
- Conditions
- Lupus Erythematosus Disseminatus, Autoimmune Diseases, Chronic Disease
- Trial name
- GALA (NCT05394922)
- Where
- 2 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Montpellier
Lupus Erythematosus, Systemic
Validation of Patient E-tool to Measure Systemic Lupus Activity
Validation of a self-questionnaire (SLEDAI-P/LUPIN) completed by the patient to measure the activity of the systemic lupus, in order to improve the patient's empowerment.
- Trial name
- OPTIMISE (NCT05763225)
- Where
- 31 sites in France, Guadeloupe and 1 more
- Volunteers
- 450 people
- Sponsor
- Association Francaise du Lupus et Autres Maladies Auto-immunes (AFL+)